Leerink Partnrs Predicts Weaker Earnings for MacroGenics
MacroGenics, Inc. (NASDAQ:MGNX – Free Report) – Equities researchers at Leerink Partnrs dropped their Q2 2025 earnings estimates for MacroGenics in a note issued to investors on Tuesday, May 13th. Leerink Partnrs analyst J. Chang now anticipates that the biopharmaceutical company will earn ($0.65) per share for the quarter, down from their previous estimate of […]
MacroGenics, Inc. (NASDAQ:MGNX – Free Report) – Equities researchers at Leerink Partnrs dropped their Q2 2025 earnings estimates for MacroGenics in a note issued to investors on Tuesday, May 13th. Leerink Partnrs analyst J. Chang now anticipates that the biopharmaceutical company will earn ($0.65) per share for the quarter, down from their previous estimate of […]
